Systematix Q1FY27: consolidated PAT swings to ₹4.89 Cr loss YoY as IB fees plunge 79%

Systematix Corporate Services' consolidated (primary) results for Q1 FY27 show a swing to a net loss of ₹4.89 Cr, against a profit of ₹10.46 Cr in the year-ago quarter — even as consolidated revenue rose 43.6% YoY to ₹56.26 Cr. The growth was low-margin: net profit margin fell from +26.5% a year ago to -8.3% now. Standalone (parent-level, essentially the merchant banking book) tells a sharper version of the same story — PAT of -₹6.19 Cr versus +₹5.98 Cr YoY — with the Financing (+₹4.21 Cr segment PBT) and Equity/Commodity/Currency (+₹0.52 Cr) subsidiaries partly cushioning the consolidated number. The driver sits squarely in the core Merchant Banking & Related Activities segment, which posted revenue of just ₹3.82 Cr, down 78.9% from ₹18.09 Cr a year ago, and swung to a segment PBT loss of ₹6.52 Cr from a profit. Employee benefits expense in this book rose to ₹6.19 Cr (up 38.6% YoY) even as deal-related fee income collapsed — a straightforward cost-revenue scissors. Consolidated revenue growth was instead propped up by the Equity/Commodity/Currency segment's ₹50.86 Cr of revenue, most of it a low-margin ₹29.51 Cr stock-sale/treasury pass-through offset almost entirely by a matching ₹28.52 Cr purchase cost — that segment's PBT was only ₹0.52 Cr. Sequentially, the consolidated loss narrowed 58.5% from -₹11.79 Cr in Q4FY26, but that improvement also owes more to the treasury pass-through than to a recovery in fee income. We have no prior guidance or concall commentary on record for this company, and no formal outlook is on file — management gives none in this filing either, nor is there a separate press release beyond the regulatory results statement. A web search turned up no broker previews or consensus estimates for this micro-cap merchant banker, so street comparison is unavailable this quarter. The quarter also carried management transition: Ratnadeep Acharyya was appointed MD & CEO (May 15, 2026) and Rupam Lal Das as Joint MD (May 8, 2026), while a separate director resignation followed just after quarter-end (Aug 4, 2026); the board simultaneously re-appointed Nikhil Khandelwal as MD for a further three years from September 1, 2026. A regulatory overhang remains unresolved: SEBI's December 2023 cancellation of subsidiary Systematix Commodities Services' registration stays stayed by the Securities Appellate Tribunal, with the next hearing on August 20, 2026; the board states the company carries no major liability as of June 30, 2026 and continues on a going-concern basis. Subsidiary LLP Divisha Alternative Investments was struck off the LLP register on July 21, 2026, and the company separately invested ₹35.0 Cr via rights issue into wholly-owned subsidiary Systematix Shares and Stocks (India) Ltd on April 13, 2026.